The invention relates to a method of reducing or preventing the adsorption of a polypeptide on a surface, or the aggregation of a polypeptide in a liquid composition in contact with a surface comprising the steps of a) providing a composition comprising the polypeptide and at least two different amino acids; b) contacting the composition with the surface. Furthermore, the invention relates to medical devices comprising a composition comprising the polypeptide and at least two different amino acids.

The present invention provides a controlled release formulation comprising a silicone substrate which comprises a compound of Formula (I): AA-AA-AA-X—Y. The invention further provides methods of making these formulations, medical devices such as dressings incorporating said formulations and medical uses thereof.

The present disclosure relates to an oligopeptide. The oligopeptide includes an amino acid sequence. The amino acid sequence includes a binding motif, and the binding motif has a specific amino acid sequence. The present disclosure also relates to a testing kit including the oligopeptide and a medical composition including the oligopeptide.

The present disclosure relates to an oligopeptide. The oligopeptide includes an amino acid sequence. The amino acid sequence includes a binding motif, and the binding motif has a specific amino acid sequence. The present disclosure also relates to a testing kit including the oligopeptide and a medical composition including the oligopeptide.

A nanostructure for isolating or concentrating extracellular vesicles or a pathogen, includes a transferrin family protein linked on magnetic nanoparticles. The nanostructure includes a transferrin family protein, and thus has selectivity for a pathogen or extracellular vesicles capable of binding to the transferrin family protein, and the synthesized nanostructure is positively (+) charged. The nanostructure includes magnetic nanoparticles, a target material is easily and simply isolated from other materials by magnetism when a magnetic field is applied.

The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

A bio-nanocompound incorporating metal oxide particles as substrate, an amino organosilane as linker, a dialdehyde as crosslinking agent and a nucleation agent that utilizes ice nucleating activity to create ice on low energy demand at temperatures down to 0° C. and extend cold chains without increasing energy consumption, wherein even the first application is capable of freezing to different shapes and volumes; a method for producing the bio-nanocompound by self-assembly technique, by mixing the substrate, immobilizing the linker on the substrate, immobilizing the crosslinker on the linker and immobilizing by covalent bonding nucleating agent on the crosslinker; and a coolant having the bio-nanocompound.